Laekna, Inc. (FRA:4U4)

Market Cap	279.75M -55.4%
Revenue (ttm)	33.12M
Net Income	-13.17M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,250
Open	0.6500
Previous Close	0.6450
Day's Range	0.6500 - 0.6500
52-Week Range	0.6070 - 1.9770
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 25, 2026

About Laekna

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative brea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Cayman Islands
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4U4

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error